Paolo A Zucali

Summary

Affiliation: Istituto Clinico Humanitas
Country: Italy

Publications

  1. ncbi Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey
    P A Zucali
    Department of Oncology, Humanitas Cancer Center, Rozzano, Italy
    Lung Cancer 75:360-7. 2012
  2. ncbi Future developments in the management of malignant pleural mesothelioma
    Paolo Andrea Zucali
    Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Expert Rev Anticancer Ther 9:453-67. 2009
  3. ncbi Advances in the biology of malignant pleural mesothelioma
    P A Zucali
    Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Cancer Treat Rev 37:543-58. 2011
  4. ncbi Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
    Paolo A Zucali
    Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy
    Cancer 112:1555-61. 2008
  5. ncbi Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
    Paolo Andrea Zucali
    Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Clin Cancer Res 17:2581-90. 2011
  6. ncbi The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas
    Paolo Andrea Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano, Milan, 20089, Italy
    Invest New Drugs 26:175-81. 2008
  7. ncbi Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer
    Paolo Andrea Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Oncology 71:229-36. 2006
  8. ncbi Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation
    Gianluigi Taverna
    Department of Urology, Via Manzoni 56 20089 Rozzano, Milan, Italy
    BMC Cancer 10:62. 2010
  9. ncbi Assessment of tumor response in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Cancer Treat Rev 33:533-41. 2007
  10. ncbi Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up
    Annarita Destro
    Molecular Genetics Laboratory, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Lung Cancer 59:369-76. 2008

Collaborators

Detail Information

Publications15

  1. ncbi Second-line chemotherapy in malignant pleural mesothelioma: results of a retrospective multicenter survey
    P A Zucali
    Department of Oncology, Humanitas Cancer Center, Rozzano, Italy
    Lung Cancer 75:360-7. 2012
    ..Considering the important limitations of this study, due to retrospective nature and the possible selection bias, prospective clinical trials are warranted to clarify these issues...
  2. ncbi Future developments in the management of malignant pleural mesothelioma
    Paolo Andrea Zucali
    Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Expert Rev Anticancer Ther 9:453-67. 2009
    ..The principal goals of this review are to summarize the improvements in the management of MPM that have been achieved recently and to outline the therapeutic approaches in development...
  3. ncbi Advances in the biology of malignant pleural mesothelioma
    P A Zucali
    Department of Medical Oncology, Istituto Clinico Humanitas, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Cancer Treat Rev 37:543-58. 2011
    ..This paper reviews advances in the molecular biology of malignant pleural mesothelioma in terms of pathogenesis, the major molecular pathways and the associated therapeutic strategies, and the roles of biomarkers...
  4. ncbi Gemcitabine and vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma
    Paolo A Zucali
    Department of Medical Oncology and Hematology, Humanitas Clinical Institute of Rozzano, Milan, Italy
    Cancer 112:1555-61. 2008
    ..Gemcitabine and vinorelbine have shown activity in the first-line setting. The objective of this study was to evaluate the activity and toxicity of the gemcitabine-vinorelbine combination in pemetrexed-pretreated patients with MPM...
  5. ncbi Thymidylate synthase and excision repair cross-complementing group-1 as predictors of responsiveness in mesothelioma patients treated with pemetrexed/carboplatin
    Paolo Andrea Zucali
    Department of Oncology, Biostatistics Unit, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Clin Cancer Res 17:2581-90. 2011
    ....
  6. ncbi The "old drug" dacarbazine as a second/third line chemotherapy in advanced soft tissue sarcomas
    Paolo Andrea Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Via Manzoni, 56 Rozzano, Milan, 20089, Italy
    Invest New Drugs 26:175-81. 2008
    ....
  7. ncbi Short schedule of cisplatin and vinorelbine: a dose-finding study in non-small-cell lung cancer
    Paolo Andrea Zucali
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas, Rozzano, Milan, Italy
    Oncology 71:229-36. 2006
    ..A dose-finding study of a new cisplatin/vinorelbine schedule was done to increase activity of the combination, and improve compliance of non-small-cell lung cancer PATIENTS...
  8. ncbi Bladder metastases of appendiceal mucinous adenocarcinoma: a case presentation
    Gianluigi Taverna
    Department of Urology, Via Manzoni 56 20089 Rozzano, Milan, Italy
    BMC Cancer 10:62. 2010
    ..Appendiceal adenocarcinoma is rare with a frequency of 0.08% of all surgically removed appendices. Few cases of appendiceal carcinoma infiltrating the bladder wall for spatial contiguity have been documented...
  9. ncbi Assessment of tumor response in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    Cancer Treat Rev 33:533-41. 2007
    ..New serum markers such as osteopontin and mesothelin-related proteins are under evaluation and in the future might play a role in assessing the response of MPM to treatment...
  10. ncbi Gene methylation in pleural mesothelioma: correlations with clinico-pathological features and patient's follow-up
    Annarita Destro
    Molecular Genetics Laboratory, Istituto Clinico Humanitas IRCCS, Via Manzoni 56, 20089 Rozzano, Milan, Italy
    Lung Cancer 59:369-76. 2008
    ..This result suggests the need to select homogeneously treated and staged patients with MPM to address whether their methylation profile may impact on patient's survival...
  11. ncbi Early response evaluation in malignant pleural mesothelioma by positron emission tomography with [18F]fluorodeoxyglucose
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas IRCCS, Rozzano, Milan, Italy
    J Clin Oncol 24:4587-93. 2006
    ..There is growing evidence that therapy-induced changes in tumor [(18)F]fluorodeoxyglucose (FDG) uptake as measured by positron emission tomography (PET) may predict response and patient outcome early in the course of treatment...
  12. ncbi Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma
    Vanesa Gregorc
    Department of Oncology, Istituto Scientifico San Raffaele, Universita Vita Salute San Raffaele, Milan, Italy
    J Clin Oncol 28:2604-11. 2010
    ..Currently, there are no standard options for patients with MPM who are failing a front-line pemetrexed-based regimen. We explored safety and efficacy of NGR-hTNF in this setting...
  13. ncbi Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma
    Giovanni L Ceresoli
    Department of Medical Oncology and Hematology, Istituto Clinico Humanitas Istituto di Ricovero e Cura a Carattere Scientifico, Rozzano, Milan, Italy
    J Clin Oncol 24:1443-8. 2006
    ..This multicenter, phase II clinical study was conducted to evaluate the activity of the combination of pemetrexed and carboplatin in patients with malignant pleural mesothelioma (MPM)...
  14. ncbi Phase I pharmacokinetic and pharmacodynamic study of lapatinib in combination with sorafenib in patients with advanced refractory solid tumors
    Matteo Simonelli
    Oncology and Hematology Unit, Humanitas Cancer Center, Istituto Clinico Humanitas, Rozzano, Italy
    Eur J Cancer 49:989-98. 2013
    ....
  15. ncbi Insulin-like growth factor-1 receptor and phosphorylated AKT-serine 473 expression in 132 resected thymomas and thymic carcinomas
    Paolo A Zucali
    Department of Oncology, Humanitas Clinical Institute, IRCCS, Rozzano, Milan, Italy
    Cancer 116:4686-95. 2010
    ..Thymic malignancies are rare tumors. The insulin-like growth factor-1 (IGF-1)/IGF-1 receptor (IGF-1R) system is involved in the development of the thymus. IGF-1R expression in thymic epithelial malignancies is unknown...